What are the recommended dosing, administration schedule, renal dose adjustments, monitoring, and supportive care guidelines for etoposide in chemotherapy?

Etoposide Dosing and Administration Guidelines

Etoposide dosing varies significantly by indication, with standard doses of 100 mg/m² IV on days 1-5 for germ cell tumors and 35-50 mg/m² IV daily for 4-5 days in small cell lung cancer, repeated every 21 days. 1

Standard Dosing by Indication

Germ Cell Tumors (Testicular/Ovarian)

• EP regimen: Etoposide 100 mg/m² IV days 1-5 + Cisplatin 20 mg/m² IV days 1-5, repeat every 21 days 1, 2
• BEP regimen: Etoposide 100 mg/m² IV days 1-5 + Cisplatin 20 mg/m² IV days 1-5 + Bleomycin 30 units weekly, repeat every 21 days 1, 2
• VIP regimen: Etoposide 75 mg/m² IV days 1-5 (lower dose when combined with ifosfamide) 1
• Etoposide/Carboplatin: Etoposide 120 mg/m² days 1-3 + Carboplatin 400 mg/m² day 1, repeat every 28 days for dysgerminoma 2

Small Cell Lung Cancer

• Limited-stage: Etoposide 100 mg/m² days 1-3 + Cisplatin 100 mg/m² day 1, or Etoposide 100 mg/m² days 1-3 + Carboplatin AUC 5-6 day 1, repeat every 21 days 3
• Extensive-stage: Etoposide 35-50 mg/m² IV daily for 4-5 days in combination regimens 4

High-Dose Regimens (with stem cell support)

• Carboplatin/Etoposide: Etoposide 750 mg/m² IV on days -5, -4, and -3 before stem cell infusion 1
• Paclitaxel/Carboplatin/Etoposide: Etoposide 400 mg/m² IV days 1-3 with stem cell support at 14-21 day intervals 1

Gestational Trophoblastic Disease

• EMA/CO regimen: Etoposide 100 mg/m² IV infusion over 30 minutes on days 1 and 2, alternating weekly with cyclophosphamide/vincristine 5

Administration Guidelines

Preparation and Infusion

Dilute etoposide to 0.2-0.4 mg/mL in 5% dextrose or 0.9% sodium chloride before administration 4. Concentrations above 0.4 mg/mL may precipitate. Administer over 30-60 minutes to prevent hypotension—rapid IV push is contraindicated 4.

Critical Safety Considerations

• Avoid plastic devices made of acrylic or ABS polymer, which can crack and leak with undiluted etoposide 4
• Use gloves during preparation; if skin contact occurs, wash immediately with soap and water 4
• Inspect for particulate matter and discoloration before administration 4

Stability

• Unopened vials: 24 months at room temperature (25°C) 4
• Diluted solutions (0.2-0.4 mg/mL): 96 hours at room temperature in glass or plastic containers 4

Renal Dose Adjustments

For creatinine clearance 15-50 mL/min, reduce etoposide dose by 25% 6. Etoposide is contraindicated with creatinine clearance <15 mL/min per some guidelines 6, though pharmacokinetically-guided dosing has been used successfully in dialysis patients 7.

Dialysis Considerations

• Peritoneal dialysis does NOT remove etoposide; no supplemental dosing needed 7
• Hemodialysis does NOT significantly clear etoposide (unlike carboplatin); maintain standard reduced doses 7
• Pharmacokinetic monitoring is essential in dialysis patients to ensure adequate exposure 7

Hepatic Dose Adjustments

Reduce initial etoposide dose by 50% in patients with severe hepatic impairment (cirrhosis, elevated bilirubin), then adjust based on tolerability and therapeutic drug monitoring 8, 9. The evidence shows that even patients with severe liver dysfunction can be treated successfully with dose reductions and close monitoring 9.

Drug-Drug Interactions

CYP3A4 and P-glycoprotein inhibitors may increase etoposide exposure—consider 50% dose reduction initially with therapeutic drug monitoring when multiple interacting medications are present 8.

Monitoring Requirements

Hematologic Monitoring

• CBC with differential before each cycle and at nadir (typically days 10-14) 4
• Febrile neutropenia occurs in 16% of patients; consider G-CSF prophylaxis in high-risk situations 10
• Thrombocytopenia is dose-limiting; hold or reduce dose for platelet count <50,000/μL 4

Non-Hematologic Monitoring

• Blood pressure during infusion (hypotension risk with rapid administration) 4
• Renal function (creatinine clearance) before each cycle for dose adjustment 6
• Liver function tests in patients with hepatic impairment 9
• Thromboembolic events occur in 8.9%; maintain high clinical suspicion 10

Therapeutic Drug Monitoring

Consider pharmacokinetic monitoring (target AUC 18-21 mg·mL⁻¹·min) in patients with:

• Renal impairment requiring dialysis 7
• Severe hepatic dysfunction 8, 9
• Multiple CYP3A4/P-gp inhibitors 8
• Prior cisplatin exposure (alters etoposide clearance) 11

Supportive Care

Antiemetic Prophylaxis

Etoposide has moderate emetogenic potential—provide 5-HT3 antagonist plus dexamethasone before each dose 4. Nausea/vomiting is common but generally mild and controllable 12.

Myelosuppression Management

• Nadir occurs days 10-14, recovery by day 21 4
• G-CSF is recommended to prevent dose delays, particularly with dose-dense schedules 13
• Transfuse for symptomatic anemia or platelets <10,000/μL (or <50,000/μL if bleeding) 4

Other Toxicities

• Alopecia is common—counsel patients to expect hair loss 12
• Mucositis is rare but can be severe; maintain good oral hygiene 12
• Hypersensitivity reactions occur in <5%; premedicate with antihistamines if prior reaction 4

Common Pitfalls

1. Administering undiluted or too rapidly—always dilute to 0.2-0.4 mg/mL and infuse over ≥30 minutes 4
2. Failing to adjust for renal dysfunction—37 cisplatin prescriptions were given inappropriately to patients with CrCl <60 mL/min in one audit; similar errors occur with etoposide 6
3. Using acrylic/ABS plastic devices—these crack with undiluted etoposide; use glass or appropriate plastic 4
4. Underdosing in curative settings due to organ dysfunction—therapeutic drug monitoring allows safe full-dose administration 8
5. Ignoring drug interactions—multiple CYP3A4 inhibitors can significantly increase exposure 8